Stockscreener 앱 받기
1.1405
1.60%
0.0105
Phio Pharmaceuticals Corp 주식(PHIO)의 최신 뉴스
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile
Is Phio Pharmaceuticals (PHIO) stock forming a trend channel | Q4 2025: EPS Tops ViewsStrategic Review - Newser
Cancer drug developer Phio sets April 29 live Q&A on clinical progress - Stock Titan
PHIO Stock Price, Quote & Chart | PHIO PHARMACEUTICALS CORP (NASDAQ:PHIO) - ChartMill
Phio Pharmaceuticals (PHIO) Stock Resistance Rejection (Modest Decline) 2026-04-20Expert Breakout Alerts - Cổng thông tin điện tử tỉnh Lào Cai
PHIO Phio Pharmaceuticals posts narrower than expected Q4 2025 loss as shares dip nearly 2 percent in today’s trading.Customer Loyalty - Newser
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026 - TMX Newsfile
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 - TMX Newsfile
PHIO: RNA immunotherapy shows strong tumor clearance and safety, advancing to next clinical phase - TradingView
Phio Pharmaceuticals to Discuss 'Nobel Prize Winning Science' for Skin Cancer Treatment - National Today
EPS Watch: Is Phio Pharmaceuticals Corp a stock for growth or value investors2026 Trade Ideas & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
User - The Chronicle-Journal
How do market conditions affect Phio Pharmaceuticals (PHIO) Stock | Price at $1.24, Up 2.48%Verified Stock Signals - Newser
Form 8-KCurrent report - ADVFN
Ideas Watch: Does Phio Pharmaceuticals Corp have declining or rising EPSNew Guidance & Risk Controlled Swing Alerts - baoquankhu1.vn
Phio Pharmaceuticals Corp. Enters Material Definitive Agreement – SEC 8-K Filing Details April 8, 2026 - Minichart
Phio Pharmaceuticals Establishes New At-the-Market Equity Program - TipRanks
Phio Pharmaceuticals CorpEnters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026 - TradingView
Phio Pharmaceuticals (NASDAQ: PHIO) launches $6.36M at-the-market stock plan - Stock Titan
Phio Pharmaceuticals (PHIO) files $6.36M ATM with H.C. Wainwright - Stock Titan
Pyramid Pharma Services Announces Drug Product Manufacturing Agreement for Phio Pharmaceuticals’ Lead Oncology - EIN News
What dividend growth rate does Phio Pharmaceuticals Corp offer2026 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn
Will Phio Pharmaceuticals (PHIO) Stock Go Higher | Price at $1.25, Down 2.34%Pro Level Trade Signals - Newser
Profit Review: Is Phio Pharmaceuticals Corp on track to beat earningsSwing Trade & Detailed Earnings Play Alerts - baoquankhu1.vn
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762 - TMX Newsfile
VIX Spike: Is Phio Pharmaceuticals Corp being accumulated by smart moneyQuarterly Risk Review & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Phio Pharmaceuticals Secures cGMP Manufacturing for Clinical Supply - The Globe and Mail
Phio Pharmaceuticals Signs U.S. cGMP Manufacturing Agreement for PH-762 Drug Product Clinical Supply - Minichart
Phio Pharmaceuticals secures U.S. cGMP manufacturer for PH-762 clinical and commercial supply - TradingView — Track All Markets
Phio (NASDAQ: PHIO) inks PH-762 manufacturing deal after strong 65% response - Stock Titan
Phio lines up U.S. supply for skin cancer drug as PH-762 trials advance - Stock Titan
Dow Update: Can Phio Pharmaceuticals Corp lead its sector in growth - baoquankhu1.vn
Phio Pharmaceuticals Corp (44R1.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Phio Pharmaceuticals Corp (44R1.MU) stock price, news, quote and history - Yahoo Finance UK
Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Phio Pharmaceuticals to present PH-762 cancer trial data Friday By Investing.com - Investing.com South Africa
Phio Pharmaceuticals to present PH-762 cancer trial data Friday - Investing.com
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement - TMX Newsfile
A skin cancer study with 65% response sends Phio to a late-breaker stage - Stock Titan
Cancer biotech Phio Pharmaceuticals stock surges as trial shows tumor clearance at highest dose in skin cancer patients - MSN
Aug Macro: Is Phio Pharmaceuticals Corp a stock for growth or value investors2026 Historical Comparison & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Retail Trends: Is Phio Pharmaceuticals Corp being accumulated by smart money2026 Performance Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office - Bitget
Phio cancer study sees ~65% response; CEO in March 18 virtual chat - Stock Titan
0.78%
3.99%
자본화:
|
볼륨(24시간):